UNION Therapeutics Announces Exciting Results in Atopic Dermatitis
UNION therapeutics A/S (UNION) is ready to share transformative results from their ADESOS Phase 2b trial featuring Orismilast at the upcoming European Academy of Dermatology and Venerology (EADV) Congress. This presentation has been designated as a late-breaking oral presentation, which emphasizes its importance in dermatology.
Orismilast Shows Promise in Treating Atopic Dermatitis
The results from the ADESOS Phase 2b trial will be thoroughly discussed, demonstrating Orismilast's potential as a new oral treatment for those suffering from atopic dermatitis (AD). The findings will showcase not only its ability to alleviate symptoms but also the positive initial effects on patient-reported outcomes.
Overview of the ADESOS Phase 2b Study
The ADESOS study aimed to evaluate Orismilast's safety and effectiveness as a high-potency phosphodiesterase 4 (PDE4) inhibitor. By targeting the PDE4B and PDE4D subtypes associated with inflammation, this treatment offers a hopeful solution for various immunological conditions, particularly AD.
Importance of Late-Breaking Presentation
Being selected for a late-breaking oral presentation at a prestigious event like the EADV Congress adds significant credibility to these findings. This platform allows UNION to engage with leaders and innovators in the field of dermatology, facilitating discussions about the implications of their research and potential treatment alternatives for patients.
Further Insights at the EADV Congress
Alongside the oral presentation, two posters will also be featured. These will explore the molecular effects seen in the skin of AD patients after treatment and present additional results from the Phase 2b study. The development of Orismilast marks a crucial milestone for UNION as they prepare to advance to Phase 3 study for AD.
Perspectives from UNION's Leadership
Kim Kjøller, Co-CEO of UNION therapeutics, expressed her enthusiasm about presenting these findings. She emphasized the importance of discussing the technical advancements achieved during the clinical trial phase and their potential benefits for patients in the near future.
About Orismilast and UNION Therapeutics
Orismilast represents a next-generation treatment that not only shows promise for atopic dermatitis but is also being investigated for other conditions like hidradenitis suppurativa and ulcerative colitis. UNION Therapeutics aims to provide a safe and effective oral treatment that boasts a well-established safety profile within the PDE4 class.
The company's commitment to developing Orismilast is evident through their strategic approach, focused on ensuring that patients with moderate to severe AD receive safe and effective treatment options.
Frequently Asked Questions
What makes the presentation at the EADV Congress significant?
The late-breaking oral presentation features groundbreaking results from the ADESOS Phase 2b trial, highlighting Orismilast as a promising treatment for atopic dermatitis.
What is Orismilast?
Orismilast is a high-potency inhibitor selective for PDE4 B/D, designed to address inflammation-related conditions, notably atopic dermatitis.
What have the clinical studies shown for Orismilast?
Initial clinical studies have reported positive efficacy and safety results, leading to further research and development across various immunological diseases.
What are the future plans for Orismilast?
UNION intends to move Orismilast into Phase 3 development, aiming to confirm its effectiveness as a treatment for atopic dermatitis.
Who is at the helm of UNION Therapeutics?
UNION is led by an experienced team of biotech entrepreneurs and pharmaceutical executives committed to creating innovative treatments for immunological conditions.
